GOA Therapeutics Emerges from Stealth with $15.5 Million in Funding and Unveils GOA26, a First-in-Class Drug Candidate for Acute Alcohol Intoxication and Poisoning
Company presented IND-enabling preclinical data earlier today at the AAST annual meeting DALLAS — GOA Therapeutics Corporation (GOA or the Company) emerged from stealth and presented preclinical findings for GOA26,…